KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Quest Diagnostics (DGX) EBITDA Margin: 2009-2025

Historic EBITDA Margin for Quest Diagnostics (DGX) over the last 17 years, with Sep 2025 value amounting to 13.71%.

  • Quest Diagnostics' EBITDA Margin rose 44.00% to 13.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.11%, marking a year-over-year increase of 99.00%. This contributed to the annual value of 13.63% for FY2024, which is 1.00% down from last year.
  • Per Quest Diagnostics' latest filing, its EBITDA Margin stood at 13.71% for Q3 2025, which was down 13.59% from 15.86% recorded in Q2 2025.
  • Quest Diagnostics' EBITDA Margin's 5-year high stood at 24.26% during Q1 2021, with a 5-year trough of 5.79% in Q4 2022.
  • Moreover, its 3-year median value for EBITDA Margin was 13.71% (2025), whereas its average is 13.79%.
  • Per our database at Business Quant, Quest Diagnostics' EBITDA Margin spiked by 1,466bps in 2021 and then crashed by 1,375bps in 2022.
  • Over the past 5 years, Quest Diagnostics' EBITDA Margin (Quarterly) stood at 19.53% in 2021, then crashed by 1,375bps to 5.79% in 2022, then skyrocketed by 588bps to 11.67% in 2023, then soared by 210bps to 13.77% in 2024, then skyrocketed by 44bps to 13.71% in 2025.
  • Its EBITDA Margin was 13.71% in Q3 2025, compared to 15.86% in Q2 2025 and 13.05% in Q1 2025.